secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001104659-24-112034
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa Q3 ARCALYST revenue $112.2M (+73% YoY); FY guidance raised to $410-420M
-------------------------------------------------------------------------------

- ARCALYST Q3 net product revenue $112.2M, up 73% YoY; FY 2024 guidance raised to $410-420M from $405-415M.
- Net loss narrowed to $12.7M from $13.9M; cash $223.8M, no debt.
- Over 2,550 prescribers since launch; average therapy duration ~27 months.
- Phase 2b trial of abiprubart in Sjögren's Disease enrolling/dosing; expects annual cash flow positivity.
- Launched Life DisRPted campaign with Henrik Lundqvist and Carly Pearce.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924112034/0001104659-24-112034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924112034/tm2426983d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-112034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer